Developer docs
API playgroundTry for free, no card

Search company profiles

Apteeus

Full company profile

uuid000f3pd

Namestring
Apteeus
Legal namestring
APTEΞUS SARL
Websiteurl
apteeus.fr
Company typeenum
Private
Founded yearint
2013
Descriptiontext

Apteeus is a clinical-stage biotech company headquartered on the campus of Institut Pasteur de Lille in France, founded in 2013 by Dr. Terence Beghyn (CEO) and Professor Benoit Deprez (Strategic Advisor), both pharmacists with doctoral training. The company specializes in drug repurposing for rare monogenic diseases, conducting collaborative research programs with patient associations, hospital reference centers (notably CHRU de Lille's Centre de Référence Maladies Héréditaires du Métabolisme), academic institutions, and EU-funded consortia to identify therapeutic candidates for conditions with unmet medical need, particularly inherited metabolic disorders.

Apteeus' proprietary platform integrates three branded components: Operando® (collection of cutaneous biopsies from patients to isolate disease-modeling primary cells), evidenceFactory® (miniaturized and automated high-throughput screening using cell imaging and liquid chromatography-mass spectrometry to measure causal defects of disease symptoms in vitro), and TEE Library® (a proprietary, daily-enriched collection of approximately 2,600 drug molecules approved for human use). The platform enables screening of approved compounds against patient-specific cells, with drug candidate identification reported in less than six months from project initiation. The pipeline includes named candidates such as TEE2555 (Zellweger Spectrum), TEE002 (dystrophic epidermolysis bullosa), TEE1482 (ceramidase deficiency), TEE886 (ACOX1 deficiency), and TEE1121 (D-bifunctional protein deficiency).

Apteeus operates a pre-commercial model without disclosed product pricing or licensing revenue. Activities are sustained through institutional grants, EU consortium participation (most notably the €8.8 million Horizon Europe grant for the SIMPATHIC consortium awarded in April 2023), and French government innovation awards (including the 2016 Concours Mondial de l'Innovation 2030). A wholly-owned subsidiary, APTEEA Therapeutics, is developing TEA001, an inhaled anti-infectious candidate. Several identified drug candidates have been administered through compassionate use pathways to pediatric patients, but no formal marketing authorizations have been disclosed and no equity financing rounds are recorded.

Short descriptiontext

Apteeus is a Lille-based clinical-stage biotech that repurposes approved drugs for rare monogenic diseases using its Operando®, evidenceFactory®, and TEE Library® platform built on patient-derived primary cells. It partners with patient associations, hospital reference centers, and EU consortia to identify drug candidates within months.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersLille, France
HQ citystring
Lille
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
drug repurposing services, rare disease therapeutics, patient-derived cell screening, high-throughput drug screening, biotech research collaborations
Industry4 codes
PRIMARYHLAAAIAA
High-Throughput Screening & Assay Platforms (HTS/HCS, phenotypic screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAIALAF
Translational Medicine & Biomarkers
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAGAAAD
Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Drug Repurposing & Rare Disease Biotech
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Collaborative Research Programs
TypeProfessional Services
Description

Apteeus conducts research programs in collaboration with patient associations, doctors, and academic/industrial partners. The company aims to develop drug candidates until clinical efficacy is demonstrated, funded through institutional grants and consortium funding.

apteeus.fr
2European Consortium Funding (SIMPATHIC)
TypeLicensing Royalties
Description

Apteeus participates in the SIMPATHIC consortium funded by Horizon Europe (8.8 million euros total), contributing expertise in individualized drug discovery for rare neurological disorders.

apteeus.fr
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 3 records shown
1Operando
Description

Biomedical research program for collecting cutaneous biopsies from patients to isolate disease model cells.

apteeus.fr
+2 more records
Core offering1 text field

Apteeus delivers customized drug repurposing and high-throughput screening programs for rare monogenic diseases, using patient-derived primary cells, automated cell imaging, and mass spectrometry to test a proprietary library of approximately 2,600 approved molecules and identify drug candidates in a few months. The company runs collaborative research with patient associations, hospital reference centers, and academic partners, and participates in EU-funded consortia (e.g., SIMPATHIC) to advance internal candidates toward clinical efficacy, while operating a wholly owned subsidiary (APTEEA Therapeutics) for an inhaled anti-infectious candidate.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Drug candidate identified in less than 6 months from project initiation (e.g., for Noé's D-Bifunctional Protein Deficiency)
+3 more records
Product overview1 text field

Apteeus operates as a drug repurposing biotech offering a unified platform of three proprietary technologies: Operando® (patient biopsy collection for cellular disease models), evidenceFactory® (automated high-throughput screening via cell imaging and mass spectrometry), and TEE Library® (proprietary collection of ~2600 approved human-use molecules). The company screens these molecules against patient-derived primary cells to identify drug candidates for rare monogenic diseases. Multiple drug candidates have emerged from this platform including TEE2555 (Zellweger Syndrome), TEE002 (Epidermolysis Bullosa), TEA001 via subsidiary APTEEA Therapeutics (anti-infectious), and several candidates for lysosomal storage disorders (TEE1482, TEE886, TEE1121). The company also participates in collaborative programs like SIMPATHIC and COVID drug repurposing initiatives.

Product and service2 records
1Drug Repurposing Services
CategoryDrug discovery and repurposing services
Description

Customized drug discovery programs that use patient-derived primary cells to identify existing approved drugs that can be repositioned for rare monogenic diseases with unmet medical need. Offered to patient associations, hospital reference centers, academic researchers and consortia; projects typically run on a multi-month basis and produce candidate molecules progressed toward compassionate use or clinical evaluation.

2Drug Screening Services
CategoryDrug discovery and repurposing services
Description

High-throughput screening of thousands of molecules against patient-derived cellular models, using miniaturized and automated cell imaging and mass spectrometry readouts, to identify drug candidates and potential new therapeutic targets for rare disease programs.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership9 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-07-01
Description

SIMPATHIC is a 22-partner international consortium funded by Horizon Europe (€8.8 million grant) to accelerate drug repurposing for rare neurological disorders. Led by Radboudumc and UMC Amsterdam, the consortium uses a new method to test existing medications on patient-derived cells (blood or skin samples). Apteeus contributes its drug discovery expertise and TEE Library® screening capabilities. The 5-year program began July 2023.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Apteeus is based on the campus of Institut Pasteur de Lille. Scientific Director Benoit Deprez leads the M2SV Unit 1177 at the institute. The institute provides laboratory facilities and research infrastructure. The CoViD project Therapide clinical trial is promoted by Institut Pasteur de Lille.

3M2SV Unit 1177 — Institut Pasteur de Lille / Inserm / Université de Lille
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Research unit led by Professor Benoit Deprez, involved in COVID-19 drug repurposing project (Therapide clinical trial). Collaborates on antiviral screening using Apteeus' TEE Library®.

apteeus.fr
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Research unit led by Professor Jean Dubuisson, partner in the CoViD drug repurposing project. Collaborates on understanding viral mechanisms and therapeutic applications.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

University medical center in the Netherlands leading the SIMPATHIC consortium. Peter-Bram 't Hoen serves as project leader/bioinformatician. Co-leading with UMC Amsterdam on drug repurposing for rare neurological disorders.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

University medical center co-leading the SIMPATHIC consortium. Clara van Karnebeek serves as project leader/biochemist geneticist. Contributes clinical genetics expertise for rare neurological disorder research.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Reference center for hereditary metabolic diseases led by Dr. Dries Dobbelaere. Provides clinical oversight for compassionate use treatments identified by Apteeus, including for patients with ACOX1 deficiency, D-bifunctional protein deficiency, and SMA-PME/Farber disease. Part of MetabERN network.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

French national institute for health and medical research. The drug discovery laboratory set up by Benoit Deprez at Institut Pasteur de Lille was labelled by INSERM. Multiple INSERM-affiliated research units collaborate with Apteeus.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Academic university collaborating through shared research units (M2SV U1177, CIIL UMR9017) with Apteeus co-founders and team members.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

ML-enabled drug discovery company combining high-throughput biology with predictive models. Comparable in combining patient-derived biology with computational approaches, though at much larger scale and broader indication scope.

TypeBroad incumbent
Description

AI-native drug discovery company with a focus on repurposing and developing therapeutics across multiple disease areas. Comparable technology-driven approach to drug identification, but at significantly greater scale.

TypeBroad incumbent
Description

Computational drug discovery platform combining physics-based simulation with machine learning. Comparable as an established drug repurposing/discovery technology provider serving pharma partners.

TypeDirect peer
Description

Non-profit organization developing an algorithmic platform to identify new uses for existing drugs across rare diseases. Comparable mission of repurposing approved drugs for neglected/rare conditions, though structured as a non-profit.

5Biovista
TypeDirect peer
Description

Pioneer in systematic drug repositioning with a focus on orphan and CNS indications. Comparable as one of the few pure-play drug repurposing companies with overlapping therapeutic areas in neurological rare diseases.

TypeBroad incumbent
Description

Large AI-driven drug discovery company using high-throughput biology and machine learning to identify novel therapeutics. Comparable in high-throughput screening philosophy but operates at vastly larger scale and broader therapeutic scope.

TypeOthers
Description

Product Development Partnership focused on antimalarial drug discovery including repurposing approaches. Comparable as a multi-partner consortia model for neglected/rare disease drug development, with shared infrastructure and risk.

TypeDirect peer
Description

AI-driven drug repurposing company focused specifically on rare diseases. Comparable to Apteeus in combining drug repurposing methodology with rare disease focus, though Healx uses in-silico prediction while Apteeus uses patient-derived cell screening.

9Cures Within Reach
TypeOthers
Description

Non-profit focused on testing already-approved drugs for new indications. Comparable mission of drug repurposing for diseases with unmet need, especially rare conditions, but operates as a charity funding clinical trials.

10Pharnext
TypeDirect peer
Description

French biotech developing novel combinations of repositioned drugs for rare neurological diseases (Charcot-Marie-Tooth). Highly comparable in geography, repurposing strategy, and rare disease focus, with a more advanced commercial-stage asset.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Apteeus

Drug Repurposing & Rare Disease Biotechapteeus.fr

Apteeus is a Lille-based clinical-stage biotech that repurposes approved drugs for rare monogenic diseases using its Operando®, evidenceFactory®, and TEE Library® platform built on patient-derived primary cells. It partners with patient associations, hospital reference centers, and EU consortia to identify drug candidates within months.

What Apteeus does

Apteeus is a clinical-stage biotech company headquartered on the campus of Institut Pasteur de Lille in France, founded in 2013 by Dr. Terence Beghyn (CEO) and Professor Benoit Deprez (Strategic Advisor), both pharmacists with doctoral training. The company specializes in drug repurposing for rare monogenic diseases, conducting collaborative research programs with patient associations, hospital reference centers (notably CHRU de Lille's Centre de Référence Maladies Héréditaires du Métabolisme), academic institutions, and EU-funded consortia to identify therapeutic candidates for conditions with unmet medical need, particularly inherited metabolic disorders.

Apteeus' proprietary platform integrates three branded components: Operando® (collection of cutaneous biopsies from patients to isolate disease-modeling primary cells), evidenceFactory® (miniaturized and automated high-throughput screening using cell imaging and liquid chromatography-mass spectrometry to measure causal defects of disease symptoms in vitro), and TEE Library® (a proprietary, daily-enriched collection of approximately 2,600 drug molecules approved for human use). The platform enables screening of approved compounds against patient-specific cells, with drug candidate identification reported in less than six months from project initiation. The pipeline includes named candidates such as TEE2555 (Zellweger Spectrum), TEE002 (dystrophic epidermolysis bullosa), TEE1482 (ceramidase deficiency), TEE886 (ACOX1 deficiency), and TEE1121 (D-bifunctional protein deficiency).

Apteeus operates a pre-commercial model without disclosed product pricing or licensing revenue. Activities are sustained through institutional grants, EU consortium participation (most notably the €8.8 million Horizon Europe grant for the SIMPATHIC consortium awarded in April 2023), and French government innovation awards (including the 2016 Concours Mondial de l'Innovation 2030). A wholly-owned subsidiary, APTEEA Therapeutics, is developing TEA001, an inhaled anti-infectious candidate. Several identified drug candidates have been administered through compassionate use pathways to pediatric patients, but no formal marketing authorizations have been disclosed and no equity financing rounds are recorded.

Apteeus firmographics

Firmographics
Name
Apteeus
Legal name
APTEΞUS SARL
Website
https://apteeus.fr
Company type
Private
Founded year
2013
Operating status
Operating
Headcount range
1–10 employees
Short description
Apteeus is a Lille-based clinical-stage biotech that repurposes approved drugs for rare monogenic diseases using its Operando®, evidenceFactory®, and TEE Library® platform built on patient-derived primary cells. It partners with patient associations, hospital reference centers, and EU consortia to identify drug candidates within months.
Ownership category
akta.pro rank

Apteeus industry classification

Industry
Product category
Drug Repurposing & Rare Disease Biotech
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAIAA
High-Throughput Screening & Assay Platforms (HTS/HCS, phenotypic screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAIALAF
Translational Medicine & Biomarkers
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAGAAAD
Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Drug repurposing services
  • Rare disease therapeutics
  • Patient-derived cell screening
  • High-throughput drug screening
  • Biotech research collaborations

Where Apteeus is headquartered

Location

Headquarters

HQ city
Lille
HQ country
France
HQ region
Europe

Offices1 record

Markets served

Apteeus business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Collaborative Research Programs: Apteeus conducts research programs in collaboration with patient associations, doctors, and academic/industrial partners. The company aims to develop drug candidates until clinical efficacy is demonstrated, funded through institutional grants and consortium funding.
  2. European Consortium Funding (SIMPATHIC): Apteeus participates in the SIMPATHIC consortium funded by Horizon Europe (8.8 million euros total), contributing expertise in individualized drug discovery for rare neurological disorders.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels7 records

Apteeus product offering

Product offering

Core offering

Apteeus delivers customized drug repurposing and high-throughput screening programs for rare monogenic diseases, using patient-derived primary cells, automated cell imaging, and mass spectrometry to test a proprietary library of approximately 2,600 approved molecules and identify drug candidates in a few months. The company runs collaborative research with patient associations, hospital reference centers, and academic partners, and participates in EU-funded consortia (e.g., SIMPATHIC) to advance internal candidates toward clinical efficacy, while operating a wholly owned subsidiary (APTEEA Therapeutics) for an inhaled anti-infectious candidate.

Product overview

Apteeus operates as a drug repurposing biotech offering a unified platform of three proprietary technologies: Operando® (patient biopsy collection for cellular disease models), evidenceFactory® (automated high-throughput screening via cell imaging and mass spectrometry), and TEE Library® (proprietary collection of ~2600 approved human-use molecules). The company screens these molecules against patient-derived primary cells to identify drug candidates for rare monogenic diseases. Multiple drug candidates have emerged from this platform including TEE2555 (Zellweger Syndrome), TEE002 (Epidermolysis Bullosa), TEA001 via subsidiary APTEEA Therapeutics (anti-infectious), and several candidates for lysosomal storage disorders (TEE1482, TEE886, TEE1121). The company also participates in collaborative programs like SIMPATHIC and COVID drug repurposing initiatives.

Differentiator

Problem solved

Functional benefit

Brands

  • Operando: Biomedical research program for collecting cutaneous biopsies from patients to isolate disease model cells.
  • evidenceFactory
  • TEE Library

Products and services

  • Drug Repurposing Services Customized drug discovery programs that use patient-derived primary cells to identify existing approved drugs that can be repositioned for rare monogenic diseases with unmet medical need. Offered to patient associations, hospital reference centers, academic researchers and consortia; projects typically run on a multi-month basis and produce candidate molecules progressed toward compassionate use or clinical evaluation.
  • Drug Screening Services High-throughput screening of thousands of molecules against patient-derived cellular models, using miniaturized and automated cell imaging and mass spectrometry readouts, to identify drug candidates and potential new therapeutic targets for rare disease programs.

Quantifiable outcome

  • Drug candidate identified in less than 6 months from project initiation (e.g., for Noé's D-Bifunctional Protein Deficiency)
  • +3 more outcomes

Companies that use Apteeus

Customer profile

Named customers4 records

Segments3 records

Ideal customer profiles3 records

Apteeus technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature4 records

Apteeus partnerships and signals

Strategic signal

Partnerships

Nine partnerships are on record, tiered core.

  • SIMPATHIC ConsortiumcoreStrategic or Co-development Partner · 1 July 2023SIMPATHIC is a 22-partner international consortium funded by Horizon Europe (€8.8 million grant) to accelerate drug repurposing for rare neurological disorders. Led by Radboudumc and UMC Amsterdam, the consortium uses a new method to test existing medications on patient-derived cells (blood or skin samples). Apteeus contributes its drug discovery expertise and TEE Library® screening capabilities. The 5-year program began July 2023.
  • Institut Pasteur de LillecoreStrategic or Co-development PartnerApteeus is based on the campus of Institut Pasteur de Lille. Scientific Director Benoit Deprez leads the M2SV Unit 1177 at the institute. The institute provides laboratory facilities and research infrastructure. The CoViD project Therapide clinical trial is promoted by Institut Pasteur de Lille.
  • M2SV Unit 1177 — Institut Pasteur de Lille / Inserm / Université de LillecoreStrategic or Co-development PartnerResearch unit led by Professor Benoit Deprez, involved in COVID-19 drug repurposing project (Therapide clinical trial). Collaborates on antiviral screening using Apteeus' TEE Library®.
  • CIIL UMR9017 — Institut Pasteur de Lille / Université de Lille / CNRS / Inserm / CHU de LillecoreStrategic or Co-development PartnerResearch unit led by Professor Jean Dubuisson, partner in the CoViD drug repurposing project. Collaborates on understanding viral mechanisms and therapeutic applications.
  • Radboudumc (Netherlands)coreStrategic or Co-development PartnerUniversity medical center in the Netherlands leading the SIMPATHIC consortium. Peter-Bram 't Hoen serves as project leader/bioinformatician. Co-leading with UMC Amsterdam on drug repurposing for rare neurological disorders.
  • UMC Amsterdam (Netherlands)coreStrategic or Co-development PartnerUniversity medical center co-leading the SIMPATHIC consortium. Clara van Karnebeek serves as project leader/biochemist geneticist. Contributes clinical genetics expertise for rare neurological disorder research.
  • CHRU de Lille — Centre de Référence Maladies Héréditaires du MétabolismecoreStrategic or Co-development PartnerReference center for hereditary metabolic diseases led by Dr. Dries Dobbelaere. Provides clinical oversight for compassionate use treatments identified by Apteeus, including for patients with ACOX1 deficiency, D-bifunctional protein deficiency, and SMA-PME/Farber disease. Part of MetabERN network.
  • INSERMcoreStrategic or Co-development PartnerFrench national institute for health and medical research. The drug discovery laboratory set up by Benoit Deprez at Institut Pasteur de Lille was labelled by INSERM. Multiple INSERM-affiliated research units collaborate with Apteeus.
  • Université de LillecoreStrategic or Co-development PartnerAcademic university collaborating through shared research units (M2SV U1177, CIIL UMR9017) with Apteeus co-founders and team members.

Scale indicators7 records

Recent moves5 records

Expansion highlights5 records

Apteeus competitors and assessment

Company assessment

Broad incumbents

  • Insitro: ML-enabled drug discovery company combining high-throughput biology with predictive models. Comparable in combining patient-derived biology with computational approaches, though at much larger scale and broader indication scope.
  • Valo Health: AI-native drug discovery company with a focus on repurposing and developing therapeutics across multiple disease areas. Comparable technology-driven approach to drug identification, but at significantly greater scale.
  • Schrödinger, Inc. Computational drug discovery platform combining physics-based simulation with machine learning. Comparable as an established drug repurposing/discovery technology provider serving pharma partners.
  • Recursion Pharmaceuticals: Large AI-driven drug discovery company using high-throughput biology and machine learning to identify novel therapeutics. Comparable in high-throughput screening philosophy but operates at vastly larger scale and broader therapeutic scope.

Direct peers

  • Every Cure: Non-profit organization developing an algorithmic platform to identify new uses for existing drugs across rare diseases. Comparable mission of repurposing approved drugs for neglected/rare conditions, though structured as a non-profit.
  • Biovista: Pioneer in systematic drug repositioning with a focus on orphan and CNS indications. Comparable as one of the few pure-play drug repurposing companies with overlapping therapeutic areas in neurological rare diseases.
  • Healx: AI-driven drug repurposing company focused specifically on rare diseases. Comparable to Apteeus in combining drug repurposing methodology with rare disease focus, though Healx uses in-silico prediction while Apteeus uses patient-derived cell screening.
  • Pharnext: French biotech developing novel combinations of repositioned drugs for rare neurological diseases (Charcot-Marie-Tooth). Highly comparable in geography, repurposing strategy, and rare disease focus, with a more advanced commercial-stage asset.

Others

  • Medicines for Malaria Venture (MMV): Product Development Partnership focused on antimalarial drug discovery including repurposing approaches. Comparable as a multi-partner consortia model for neglected/rare disease drug development, with shared infrastructure and risk.
  • Cures Within Reach: Non-profit focused on testing already-approved drugs for new indications. Comparable mission of drug repurposing for diseases with unmet need, especially rare conditions, but operates as a charity funding clinical trials.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

Apteeus social profiles

Digital presence

Apteeus financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Apteeus leadership team

Management profile

Number of profiles

Profiles2 records

Apteeus subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Apteeus funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Apteeus M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Apteeus

What does Apteeus do?

Apteeus delivers customized drug repurposing and high-throughput screening programs for rare monogenic diseases, using patient-derived primary cells, automated cell imaging, and mass spectrometry to test a proprietary library of approximately 2,600 approved molecules and identify drug candidates in a few months. The company runs collaborative research with patient associations, hospital reference centers, and academic partners, and participates in EU-funded consortia (e.g., SIMPATHIC) to advance internal candidates toward clinical efficacy, while operating a wholly owned subsidiary (APTEEA Therapeutics) for an inhaled anti-infectious candidate.

Is Apteeus a public or private company?

Apteeus is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Apteeus founded?

Apteeus was founded in 2013. It employs 1 to 10 people.

Where is Apteeus based?

Apteeus is headquartered in Lille, France, in the Europe region.

How does Apteeus make money?

Two revenue lines are on record. Collaborative Research Programs are the primary driver. The others are european Consortium Funding (SIMPATHIC).

Who are Apteeus's main competitors?

Broad incumbents on record are Insitro, Valo Health, Schrödinger, Inc. and Recursion Pharmaceuticals. Direct peers are Every Cure, Biovista, Healx and Pharnext. Others are Medicines for Malaria Venture (MMV) and Cures Within Reach.

Does Apteeus have an API?

No public API is recorded for Apteeus.

What industry is Apteeus in?

Apteeus's product category is Drug Repurposing & Rare Disease Biotech. Its primary akta.pro industry code is HLAAAIAA, High-Throughput Screening & Assay Platforms (HTS/HCS, phenotypic screening), with a secondary code of HLAIALAF, Translational Medicine & Biomarkers. Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales